Akeso's stock plummeted 5.26% during intraday trading on Thursday, continuing a downward trend for the biopharmaceutical company.

The decline represents ongoing profit-taking by investors following the company's presentation of positive clinical trial data at the ASCO annual meeting. Despite reporting landmark results from its Phase III HARMONi-6 study showing significant survival benefits for its ivonescimab treatment, event-driven funds have been systematically exiting their positions since the data release.

Additional pressure came from broader sector concerns, with reports that the United States may consider restrictions on investment in Chinese biotechnology companies, weighing on sentiment across the industry.